FGFR2 and gastric cancer: Recently, a randomized phase II trial comparing AZD4547 to paclitaxel as second-line treatment for GC and gastroesophageal-junction cancer harboring FGFR2 amplification or polysomy reported no additional benefit from AZD4547 in terms of response rate, compared with the AZD4547+paclitaxel arm (SHINE;ClinicalTrials.gov identifier: NCT01457846) [9].